List view / Grid view
A new study reports that a triple-targeted drug combination can drive complete and lasting regression of pancreatic tumours in preclinical models, potentially overcoming treatment resistance in one of the deadliest cancers.
2026 is set to be a pivotal year for drug discovery, with advances in NAMs and evolving regulatory approaches promising faster, safer early drug development and accelerated delivery of therapies for patients with rare or unmet medical needs.
Biotech company, Tubulis, has published preclinical data on its Alco5 antibody-drug conjugate platform, demonstrating the ability to link antibodies with previously inaccessible hydroxy-containing drugs.
Researchers have developed virus-inspired LENN nanoparticles that deliver mRNA therapies directly to bladder cancer cells, remain stable after freeze-drying and avoid triggering immune responses.
New research shows beige fat around blood vessels helps regulate blood pressure, offering potential pathways for future therapies to reduce cardiovascular risk.
A novel imaging-guided radiopharmaceutical targeting claudin 18.2 has shown that it can precisely detect and effectively treat gastric and pancreatic tumours, completely eradicating cancer in some preclinical models.
Researchers have developed new innovative fluorescent labels that allow scientists to observe cellular processes with unprecedented clarity – offering a powerful tool for medicine, drug research and cell biology.
Drug-induced liver injury remains one of drug development’s most costly pitfalls. Now, AI and transcriptomics may offer a way to spot risks long before they reach patients.
Headlamp Health has launched Lumos AI®, a new decision-support platform designed to bring greater precision to neuroscience drug development.
Insilico Medicine and Servier have announced a multi-year collaboration to accelerate the discovery of new cancer therapies, using artificial intelligence to tackle challenging oncology targets and shorten early-stage drug development timelines.
Scientists have developed a new mathematical ‘Noise Controller’ that can stabilise random cellular fluctuations, offering a potential breakthrough in preventing cancer recurrence and antibiotic resistance.
The DMTA cycle depends on clear data flow, yet most labs still work across disconnected systems. Sean McGee, Director of Product at Certara, explains how better infrastructure and AI can help teams work faster and make decisions with more confidence.
Researchers have engineered new extracellular vesicles that can selectively induce antigen-specific regulatory T cells, possibly leading towards safer, more precise treatments for autoimmune and allergic diseases.
Peptide therapeutics are emerging as a powerful class of medicines capable of targeting diseases that challenge traditional modalities. This article reveals their rising clinical impact and the key development, safety and translational challenges that must be addressed to bring them successfully to patients.
Life-saving HIV and cancer drugs can carry serious neurological risks, and new funding will help UMBC researchers discover how these medicines damage the brain – which could help to inform safer treatments.
